Mammotome Expands Access to Innovative Breast Biopsy Marker Technology in Europe

Mammotome Unveils New Innovations in Breast Biopsy Markers

In a significant advancement in breast cancer diagnostics, Mammotome, a leader in breast health innovation and part of Danaher Corporation, has officially received CE mark approval for its HydroMARK™ Plus biopsy markers. This development aims to broaden access to cutting-edge breast care technologies across Europe, particularly for patients undergoing diagnosis and treatment for breast cancer.

Enhancing Patient Care with HydroMARK™ Plus

The HydroMARK™ Plus markers are designed utilizing a patented hydrogel technology that boasts stability and visibility, crucial for effective breast cancer surgery. These innovative markers feature Wings that Cling™, which prevent displacement during surgical procedures, enhancing tissue adherence. This is particularly crucial in the context of surgical excisions where precision is paramount.

The hydrogel component of these markers is hydrated in just 24 hours, ensuring that they remain ultrasound-visible for up to 12 months even in patients undergoing neoadjuvant chemotherapy. The ability to maintain visibility via ultrasound imaging, mammography, and MRI gives healthcare professionals greater confidence in accurately locating lesions during surgical intervention.

Olaf Andrich, the Managing Director for EMEA at Mammotome, emphasizes the importance of minimizing the risk of surgical displacement, reiterating that